Skip to main content

PDP-716

Generic name: brimonidine tartrate
Treatment for: Glaucoma, Open Angle, Glaucoma/Intraocular Hypertension

Visiox Pharma Submits New Drug Application Seeking Approval for First Once-Daily Brimonidine for Glaucoma

TARRYTOWN, N.Y., Oct. 6, 2022 /PRNewswire/ -- Visiox Pharma, LLC., a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic drugs to address highly prevalent diseases in need of new treatment options, today announced the submission of a New Drug Application to the U.S. FDA for lead product candidate, PDP-716 (0.35% brimonidine tartrate), which has the potential to be the first once-daily brimonidine to enter the market for the treatment of glaucoma.

"This NDA submission marks a significant milestone for Visiox," said Ryan Bleeks, Chief Executive Officer. "We believe the patented TearAct™ delivery technology, which provides slow, consistent, and sustained release for IOP control throughout the day will address a significant unmet need for glaucoma patients."

The NDA submission is supported by data demonstrating IOP reduction for ocular hypertension and open angle glaucoma while maintaining an excellent safety profile.

About Visiox

Visiox is a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options. Each day is an opportunity for us to disrupt and revolutionize the current market to maximize patient and physician satisfaction. As an agile business partner, we will achieve this through a high level of collaboration with all eye care professionals.

Visiox plans to submit a second New Drug Application for SDN-037 to the U.S. FDA later this year to address an unmet need for cataract surgery. SDN-037 is a twice daily topical difluprednate corticosteroid utilizing patented TJM™ (Tight Junction Modulation) proprietary formulation. The novel technology provides powerful post-surgical control of inflammation in a clear solution enabling convenient dosing with a proven active ingredient. Cataract extraction is the most frequently performed eye surgery in the U.S. It accounts for 70% of all ocular surgeries. 50 million people are projected to have cataracts in the U.S. by 20501.

PDP-716, SDN-037 and TearAct™ delivery technology were licensed by Visiox from Sun Pharma Advanced Research Company Ltd. For more information, please visit Visiox Pharma or LinkedIn.

  1. Ocular Surgery Procedures: Market Scope, 2019

SOURCE Visiox Pharma LLC

Posted: October 2022

Related articles

PDP-716 (brimonidine tartrate) FDA Approval History

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.